Results 71 to 80 of about 6,619 (182)
Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
Tolvaptan, a vasopressin V2 receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD).
Shinya Nakatani +8 more
doaj +1 more source
In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal ...
Olivier Devuyst +4 more
doaj +1 more source
ABSTRACT Aim In patients with chronic kidney disease (CKD), salt restriction has been shown to lower blood pressure and proteinuria and to provide kidney protective effects. However, the benefit of salt restriction in older adults with CKD remains unclear, particularly in advanced stages.
Hiroaki Miyauchi +5 more
wiley +1 more source
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder and an important cause of end stage renal disease (ESRD).
Anish A. Kanhai (14456670) +5 more
core +1 more source
Development of plant‐derived biomimetic nanoparticles as a novel targeted drug delivery platform
Plant‐derived biomimetic nanoparticles (PD‐BNPs) represent a sustainable and biocompatible nanoplatform for targeted drug delivery. This review highlights their therapeutic potential, engineering strategies, and translational challenges toward precision nanomedicine applications. Abstract Plant‐derived biomimetic nanoparticles (PD‐BNPs) have emerged as
Jihad Hasan +3 more
wiley +1 more source
ABSTRACT Introduction Sinusoidal obstruction syndrome, also known as veno‐occlusive disease (SOS/VOD), can occur after exposure to inotuzumab ozogamicin (InO), a calicheamicin‐based antibody‐drug conjugate. Case Presentation We experienced two cases of SOS/VOD after treatment with InO combined with intermittent administration of ponatinib without ...
Emi Yokoyama +10 more
wiley +1 more source
Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes [PDF]
Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug ...
Brouwer, Kenneth R. +7 more
core +1 more source
Background To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics.
Jieting Tang +19 more
doaj +1 more source

